NASDAQ:MURA Mural Oncology Q2 2025 Earnings Report ProfileEarnings HistoryForecast Mural Oncology EPS ResultsActual EPS-$1.77Consensus EPS -$1.13Beat/MissMissed by -$0.64One Year Ago EPSN/AMural Oncology Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMural Oncology Announcement DetailsQuarterQ2 2025Date8/4/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Mural Oncology Earnings HeadlinesRecursion names Vicki Goodman as CMOMarch 25, 2026 | msn.comMural Oncology plc: Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of AcquisitionDecember 5, 2025 | finanznachrichten.deLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain. | InvestorPlace (Ad)Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of AcquisitionDecember 5, 2025 | globenewswire.comMural Oncology Announces Sanction of the Scheme by the High CourtDecember 3, 2025 | globenewswire.comMural Oncology plc: Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA RoyaltyNovember 26, 2025 | finanznachrichten.deSee More Mural Oncology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Mural Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mural Oncology and other key companies, straight to your email. Email Address About Mural OncologyMural Oncology (NASDAQ:MURA), Inc. (NASDAQ: MURA) is a clinical-stage biotechnology company focused on discovering and developing innovative therapies for cancer. The company’s research emphasizes targeting the tumor microenvironment and stromal resistance mechanisms to enhance the efficacy of existing and novel oncology agents. Mural’s pipeline features small-molecule programs designed to inhibit signaling pathways involved in tumor growth and extracellular matrix remodeling. Its lead candidates are advancing through early-phase clinical trials in various solid tumors, leveraging translational biology tools such as patient-derived models and molecular profiling to guide drug discovery and patient selection. Headquartered in San Mateo, California, Mural Oncology conducts research and development in the United States and collaborates with academic institutions and industry partners to support global clinical development. The company’s interdisciplinary team combines expertise in oncology research, drug development and translational science to address unmet needs across multiple cancer indications.View Mural Oncology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles PriceSmart Stock Eyes $220 as Chile Expansion Fuels GrowthLockheed Martin Secures the Ultimate Defense MoatWhy Levi's Digital Strategy Is Paying Off in a Big WayConstellation Brands: Beer Growth and Buybacks Mask Stock's SlumpWhy Exxon Could Be the Market's Next Big Comeback StockWhy Penguin Solutions May Be the Smartest AI Infrastructure StockMeta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns Upcoming Earnings Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)Cintas (7/15/2026)ASML (7/15/2026)Kinder Morgan (7/15/2026)BlackRock (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
